Australia · Delayed Price · Currency is AUD Paragon Care Earnings Call Transcripts
Fiscal Year 2026
-
Underlying revenue was AUD 3.7 billion with normalized EBITDA growth of 7.4% and strong organic growth after adjusting for major one-offs. Six acquisitions expanded the business across APAC, while a share buyback is planned for FY 2027. Focus shifts to organic growth and operational efficiency.
-
Underlying revenue reached AUD 1.9 billion with EBITDA of AUD 49 million, while statutory results were impacted by a full provision for Infinity Group debt. Strong organic and segment growth, major contract wins, and ongoing integration support positive guidance, with net debt targeted at 2x EBITDA by June.
Fiscal Year 2025
-
Revenue grew 8.3% to $3.6 billion and underlying EBITDA rose 3% to $95.2 million, driven by strong Asia-Pacific and pharmacy performance. Integration synergies of $5 million were achieved, with $12 million targeted for FY 2026, and a $400 million refinancing improved capital flexibility.
Fiscal Year 2024
-
The merger created a diversified healthcare business with FY24 pro forma revenue of AUD 3.3 billion and EBITDA of AUD 91 million. Integration is progressing, with cost synergies and organic growth prioritized, despite challenges in the Australian market.